To the full analysis
Progyny stock: growth
PGNYProgyny reported $1.29B in revenue for fiscal 2025, up 10.4% on the prior year, up 30.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
50.6%
per year from 2017 to 2025, per share 7.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 30.2% | 50.6% |
| Revenue per share | 30.3% | 7.4% |
| Earnings | 4.7% | no data |
| Earnings per share | 4.7% | no data |
| Free cash flow | 40.4% | no data |
| Free cash flow per share | 40.6% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $48.58M | −$12.45M | −$10.09M |
| 2018 | $105.4M | $661K | $1.69M |
| 2019 | $229.68M | −$8.57M | −$4.49M |
| 2020 | $344.86M | $46.46M | $35.17M |
| 2021 | $500.62M | $65.77M | $23.91M |
| 2022 | $786.91M | $30.36M | $77.15M |
| 2023 | $1.09B | $62.04M | $185.17M |
| 2024 | $1.17B | $54.34M | $173.7M |
| 2025 | $1.29B | $58.52M | $191.78M |
Revenue by segment
How Progyny, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Fertility benefit services revenue64%
- Pharmacy benefit services revenue36%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Fertility benefit services revenue | $355.62M | $510.15M | $676.3M | $729.55M | $830.93M | 64.5% |
| Pharmacy benefit services revenue | $145.01M | $276.77M | $412.3M | $437.67M | $457.73M | 35.5% |
| Total revenue | $500.62M | $786.91M | $1.09B | $1.17B | $1.29B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.